1st year student with The Department of Pharmacology
Omomyc is a man-made protein that causes massive tumour regression in mice without the emergence of resistance unlike many other therapies. Omomyc has the potential to treat 70% of human cancers. However, Omomyc cannot be used as a drug itself as it is easily degraded by the body. My work focuses on creating a stable form of Omomyc to act as a new cancer drug. I conceived the idea for the project. The drug was designed in collaboration with a group in Singapore, and I am now testing the drug in cancer cells in a collaborator’s laboratory in Cambridge.
Update from Sarah Madden
"I was lucky enough to win the CSAR award in February 2017. Even though it has only been a few months since I have won the award, I have found it has already provided me with a range of new and exciting opportunities.
"It has been a real privilege to talk with the CSAR committee members and other award winners. They are a very talented bunch of people and our chats have taught me a great deal. Winning the award has also allowed me to meet the Vice-Chancellor, Professor Sir Leszek Borysiewicz, as well as Lord Martin Rees. I recently won a Messel scholarship from the Society of Chemical Industry (http://www.soci.org/news/awards/scholars/sci-scholars-2017-sarah-madden) and have no doubt that my CSAR award really made my application stand out. I’m excited for what the next academic year will bring!"
Find out about the winners awarded in previous years: